SIEMENS HEALTHCARE DIAGNOSTICS, INC. ATELLICA IM SARS-COV-2 TOTAL (COV2T); SARS-COV-2 TOTAL IMMUNOASSAY
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Positive Result (1227)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 02/18/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
An outside of the united states (ous) customer contacted the siemens customer care center (ccc) to report discordant, reactive (positive) results were obtained from two samples and the results were considered discordant compared to testing with an alternate method.One of these samples was also discordant to testing with a different lot of atellica im sars-cov-2 total.Qc was in range at the time of testing.The interpretation of results section of the instructions for use (ifu) states: "the system reports advia centaur cov2t assay results in index values or u/ml and as non-reactive or reactive: non-reactive: < 1.00 index (u/ml).These samples are considered negative for sars-cov-2 antibodies.Reactive: =1.00 index (u/ml).These samples are considered positive for sars-cov-2 antibodies." the calculation of results section of the ifu states: "conversion formula: 1.00 index value = 1.00 u/ml" the instructions for use states in the limitations section: "results are not intended to be used as the sole basis for patient management decisions.Test results should be interpreted in with clinical observations, patient history, epidemiological information, and other laboratory findings." "a reactive test result does not exclude past or present infection by other coronaviruses, such as sars-cov-1, mers-cov, hku1, 229e, nl63, or oc43, or due to cross-reactivity from pre-existing antibodies or other possible causes." a false positive/reactive result would not be used in isolation and would be correlated with clinical history.Additional laboratory testing would be used to determine specific antibody presence.Although there is no potential for serious injury in this case, an mdr will be reported to the fda as a requirement of the emergency use authorization (eua).Siemens healthcare diagnostics is investigating.Mdr 1219913-2022-00088 and mdr 1219913-2022-00089 were filed for the same event.
|
|
Event Description
|
The customer reported atellica im sars-cov-2 total (cov2t) reactive (positive) results were obtained from two samples and the results were considered discordant compared to testing with an alternate method.One of these samples was also discordant to testing with a different lot of atellica im sars-cov-2 total.The reactive results were reported to the physician(s) who questioned the results.There are no reports that treatment was altered or prescribed or adverse health consequences due to the discordant, reactive atellica im sars-cov-2 total (cov2t) results.
|
|
Manufacturer Narrative
|
Siemens filed the initial mdr 1219913-2022-00088 on march 18, 2022.March 24, 2022, additional information: an outside of the united states (ous) customer contacted the siemens customer care center (ccc) to report discordant, reactive (positive) results were obtained from two samples and the results were considered discordant compared to testing with an alternate method.One of these samples was also discordant to testing with a different lot of atellica im sars-cov-2 total.Siemens healthcare diagnostics has completed the investigation into alleged differences in cov2t results compared to an alternate method and the difference of one sample between lot 012 and 013.Quality control and calibrations were appropriate for both kit lots at the time of testing.In review of in-house data, there is no data that showed patients positive on lot 12 but negative on lot 13.No patient history was available, and no further testing could be conducted as the kit lot 012 had expired.This appears to be a sample-specific issue however without further medical history siemens healthcare is unable to determine the root cause.No product nonconformance was identified.In section h6, the investigation finding, and investigation conclusion codes were updated.Mdr 1219913-2022-00088 supplemental 1 and mdr 1219913-2022-00089 supplemental 1 were filed for the same event.
|
|
Search Alerts/Recalls
|
|
|